title: Antigenic relationship between streptococcal preparation OK-432 and tumors and its effect on immunotherapy with OK-432 in patients with superficial bladder tumor.
abstract: The cross-antigenicity between streptococcus, Su strain (OK-432), and rat bladder cancer BC-47 was studied by the immunocytochemistry. Both anti-Su (OK-432) and anti-BC-47 reacted with both homo- and heterogenous antigens. The specificity of the PAP reactions using these sera was confirmed by absorption study of the first antibodies. But, OK-432 did not share with normal rat tissues. Furthermore, the presence of common antigens between OK-432 and animal tumors where OK-432 was effective was indicated by the PAP studies, but OK-432 did not share with tumors where OK-432 was ineffective. By the PAP studies using antigroup A streptococcus-specific C-polysaccharide and antigroup-specific sera, it was suggested that the determinant of the cross-antigenicity was group A-specific C-polysaccharide. The common antigens between OK-432 and human urogenital cancers were also identified by the PAP study. Then, local immunotherapy with OK-432 was carried out in 38 patients with superficial bladder tumor and the tumors were eliminated in 23.7%. In 77.8% of the complete response and in 10.3% of the no change, the tumor tissues demonstrated antigens common between OK-432 and tissues. From these results, it was concluded that common antigens which OK-432 shared with tumors could favorably augment host defense against human bladder tumors, the same as animal tumors.
authors: Department of Urology and Microbiology, Iwate Medical University School of Medicine, Morioka, Japan.
authors: T
authors: T
authors: Fujioka
authors: H
authors: H
authors: Aoki
authors: M
authors: M
authors: Yoshida
authors: T
authors: T
authors: Ohhori
authors: T
authors: T
authors: Kubo
mesh_terms: D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001688:Biological Products / Q000276:immunology* / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D003429:Cross Reactions; D000939:Epitopes / Q000276:immunology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D051379:Mice; D008875:Middle Aged; D010844:Picibanil / Q000276:immunology* / Q000627:therapeutic use*; D051381:Rats; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000942:Antigens, Bacterial; D000951:Antigens, Neoplasm; D001688:Biological Products; D000939:Epitopes; D010844:Picibanil